Levofloxacin (Quinsair®) is recommended as an option for restricted use within NHS Wales. Levofloxacin (Quinsair®) should be restricted for use as a third-line therapy in patients who do not respond to, or are intolerant of, second-line treatment with tobramycin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Levofloxacin (Quinsair®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.